论文部分内容阅读
目的:探讨应用门冬胰岛素30(诺和锐30)强化治疗初诊2型糖尿病(T2DM)患者,以评价其临床疗效。方法:对63例初诊T2DM患者在饮食和运动治疗基础上,单纯给予诺和锐30强化治疗3个月,比较治疗前后空腹血糖(FPG)、餐后2小时血糖(2hPG)、糖化血红蛋白(HbAlc)、血脂、体重指数(BMl)、空腹及75克葡萄糖负荷后1小时/2小时/3小时血清C肽(FCP、lhCP、2hCP、3hCP)、不良反应次数。结果:与治疗前比较,FPG、2hPG、HbAlc、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)显著下降,差异有统计学意义(P<0.05);高密度脂蛋白胆固醇(HDL-C)、FCP、1hCP、2hCP、3hCP明显升高,差异有统计学意义(P<0.05);BMI增加,但差异无统计学意义(P>0.05);无明显药物不良反应。结论:诺和锐30强化治疗初诊T2DM患者能降低FPG、2hPG、HbAlc,改善胰岛β细胞功能,间接改善血脂,疗效显著。
Objective: To evaluate the clinical efficacy of insulin aspart 30 (Novo-Rui 30) intensive treatment of newly diagnosed type 2 diabetes mellitus (T2DM). Methods: Sixty-three newly diagnosed T2DM patients were treated with Novo-Rui 30 for 3 months. The fasting blood glucose (FPG), 2-hour postprandial blood glucose (2hPG), HbA1c Serum C-peptide (FCP, lhCP, 2hCP, 3hCP) at 1 h / 2 h / 3 h after fasting and 75 g of glucose loading, the number of adverse reactions. Results: The levels of FPG, 2hPG, HbAlc, total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL - C) were significantly lower than those before treatment (P <0.05). The levels of HDL-C, FCP, 1hCP, 2hCP, 3hCP were significantly higher than those in control group (P <0.05); BMI increased but the difference was not statistically significant (P> 0.05) medical side effects. Conclusion: Novo-Rui-30 intensive treatment of newly diagnosed T2DM patients can reduce FPG, 2hPG, HbAlc, improve pancreatic β-cell function, indirectly improve blood lipid, the curative effect is remarkable.